Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2025)

Historic Net Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 10.19%.

  • Kiniksa Pharmaceuticals International's Net Margin rose 215000.0% to 10.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.01%, marking a year-over-year increase of 277600.0%. This contributed to the annual value of 10.21% for FY2024, which is 121400.0% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Net Margin stood at 10.19%, which was up 215000.0% from 11.37% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Net Margin's 5-year high stood at 226.05% during Q3 2022, with a 5-year trough of 539.5% in Q2 2021.
  • Moreover, its 5-year median value for Net Margin was 21.42% (2023), whereas its average is 61.89%.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Net Margin surged by 4785800bps in 2022 and then crashed by -2467100bps in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Net Margin stood at 235.15% in 2021, then soared by 75bps to 59.7% in 2022, then increased by 1bps to 59.05% in 2023, then soared by 88bps to 7.25% in 2024, then surged by 241bps to 10.19% in 2025.
  • Its last three reported values are 10.19% in Q3 2025, 11.37% for Q2 2025, and 6.2% during Q1 2025.